Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications

Choi, Woo Suk; Cho, Min Chul; Lee, Jeong Woo; Song, Sang Hoon; Oh, Jin Kyu; Lee, Sang Wook; Cho, Sung Yong; Park, Jae Young

doi:10.1016/j.prnil.2017.02.001

Cited by 8 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…In contrast, silodosin has shown to be effective and safe for management of LUTS in elderly patients taking antihypertensive medications. 66 It is speculated that due to the high uroselectivity for α 1β adrenergic receptors is mainly responsible for controlling BP enabling silodosin to have minimum effects on CV system. Silodosin has demonstrated promising results in increasing the probability of successful TWOC in patients with AUR and those taking antihypertensive drugs.…”

Section: Methodsmentioning

confidence: 99%

“…A notable finding in this study was that adding silodosin to treatment in individuals who already had orthostatic hypotension did not worsen the condition, but rather showed improvement in 2 patients. 66 A pooled analysis of 3 Phase III studies (n = 1479), reported that 8-mg silodosin improved the frequency of nocturia (53.4% vs 42.8%; P<0.0001) and prevented worsening events (9.0% vs 14.3%; P<0.0001) compared with placebo. Silodosin 8 mg QD reduced nocturia from ≥1 episode to <2 episodes/night at the end of the study.…”

Section: Voiding Dysfunction In Bph/lutsmentioning

confidence: 99%

See 2 more Smart Citations

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Jin-dan¹,

Wang²,

Xie³

2022

DDDT

View full text Add to dashboard Cite

Use of α-androgenic receptor blockers remains a mainstay therapeutic approach for the treatment of urological diseases. Silodosin is recommended over other α-blockers for the treatment of lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH), due to its high α 1A uroselectivity. Current research data suggest that silodosin is efficacious in the management of various urological diseases. Thus, we herein review the current evidence of silodosin related to its efficacy and tolerability and appraise the available literature that might ultimately aid in management of various urological conditions at routine clinical practice. Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. Silodosin exerts effect on relaxing muscles involved in detrusor obstruction, therefore prolonging the need for patients undergoing invasive surgery. Silodosin treatment, either as a monotherapy or combination, significantly improves International Prostate Symptom Score (IPSS) including both storage and voiding symptoms in patients with BPH/LUTS. Patients on other treatment therapies such as phosphodiesterase 5 inhibitors or other α-blockers are well managed with this drug. Steadily, silodosin has proved beneficial in the treatment of other urological disorders such as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), overactive bladder/acute urinary retention (AUR), premature ejaculation (PE), and prostate cancer post brachytherapy-induced progression. In patients with distal ureteral stones, silodosin treatment is beneficial in decreasing stone expulsion time without affecting stone expulsion rate or analgesic need. Moreover, there were significant improvements in intravaginal ejaculation latency time, quality of life scores, and decrease in PE profile among patients with PE. Silodosin has also demonstrated promising results in increasing the likelihood of successful trial without catheter in patients with AUR and those taking antihypertensive drugs. Reports from Phase II studies have shown promising role of silodosin in the treatment of CP/CPPS as well as facilitating ureteral stone passage. From the robust data in this review, further silodosin treatment strategies in the management of different urological conditions need to be focused on.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Voiding Dysfunction In Bph/lutsmentioning

confidence: 99%

See 1 more Smart Citation

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Jin-dan¹,

Wang²,

Xie³

2022

DDDT

View full text Add to dashboard Cite

show abstract

“…Silodosin has been found safe and effective for management of LUTS in patients who were taking antihypertensive medicines. 44 Silodosin has minimal cardiovascular effects due to its highly selectivity. 45,46 Silodosin proved a 583-fold selectivity for the α1A versus α1B subtype and 56-fold selectivity for the α1A versus α1D.…”

Section: Cardiovascular Advantages Of Silodosinmentioning

confidence: 99%

The efficacy and safety of silodosin-a review of literature

Faikoglu¹,

Saygisever-Faikoglu²,

Ozcan³

et al. 2021

PPIJ

View full text Add to dashboard Cite

Background: Benign prostatic hyperplasia is a compilation of irritative voiding and obstructive symptoms which are consistent with reduced emptying of urine from and defective storage of urine in the bladder. Medications are a common method of treatment to delay complications and reduce symptoms. Silodosin is a highly selective alpha-1A adrenoceptor blocker that has 162 times more affinity for alpha-1a than alpha 1b, thus resulting in high uroselectivity and decreased side effects. Aim:In this review article our aim was to elucidate the clinical effects, safety and tolerability profile of silodosin in the treatment of benign prostatic hyperplasia.Method: Literatures were retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., silodosin, hypotension, benign prostatic hyperplasia), without any limitations in terms of publication date and language. Papers which assessed the therapeutic efficacy and tolerability of silodosin were selected for inclusion according to their relevance for the topic, as judged by the authors. Overvıew of clinical data:Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. It has a rapid onset of effect in men with lower urinary tract symptoms and improvements were seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life. The efficacy of silodosin was maintained in several controlled studies and also non-interventional real-world setting. Silodosin was generally well tolerated. Conclusion:Silodosin is the most uroselective α-blocker. Silodosin has been emphasized in the 2021 European Association of Urology Conservative treatment of non-neurogenic male LUTS guidelines and it has been reported that the hypotensive effect of silodosin is comparable with placebo and has favorable safety and tolerability profile. Dosing of silodosin does not need to be adjusted according to age, concurrent medication with antihypertensives and phosphodiesterase type 5 inhibitors.

show abstract

“…There have been several meta-analyses examining the effects of alpha blockers on AUR, with most studies suggesting that alpha blockers can increase the success rates of TWOC with a low incidence of adverse effects. 3 , 7 , 8 , 9 , 10 However, Zeif et al. 11 reported that there is limited evidence available indicating that alpha blockers can increase the success rate of TWOC.…”

Section: Introductionmentioning

confidence: 99%

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis

Gwon¹,

Park²,

Yang³

et al. 2023

Prostate International

View full text Add to dashboard Cite

Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications

Cited by 8 publications

References 28 publications

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

The efficacy and safety of silodosin-a review of literature

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis

Contact Info

Product

Resources

About